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EDITORIAL
On 12 April 2021, the US Centers for Disease Control called a halt 
to the use of the Johnson and Johnson (J&J)’s coronavirus vaccine[1] 
while reviewing data on the more than 6.8 million doses that had been 
administered in the USA as of 12 April, that involved 6 reported US 
cases of a vanishingly rare but severe blood clot, cerebral venous sinus 
thrombosis (CVST), seen in combination with thrombocytopenia. 
All 6 cases occurred in women between the ages of 18 and 48 years, 
and symptoms developed 6 - 13 days after vaccination. To date, the 
USA has not resumed vaccination with the J&J COVID-19 vaccine, 
but it is likely that they will do so. 
On 13 April, in a move seen as inexplicable by many local 
specialists, the South African National Department of Health 
suspended the Sisonke Protocol, through which our healthcare 
workers are being vaccinated using the J&J COVID-19 vaccine.[2] 
This decision was explained as an abundance of caution based on the 
advice of local scientists to wait until the causal relationship between 
the development of clots and the J&J vaccine is fully elucidated. In 
an ideal world, this might have seemed like a sensible precaution. 
However, unlike the USA, we have no other vaccines available. To 
complicate matters further, because our vaccine roll-out is currently 
under clinical trial protocols, it has been glacially slow, and so far 
only 289  787 health workers out of at least 1.5 million have been 
vaccinated. And we may well see a third wave of infections as we go 
into winter.
As a result there was some urgency to reversing this decision, and 
on 18 April, the South African Health Products Regulatory Authority 
(SAHPRA) recommended that the pause in the Siskonke Protocol 
be lifted, provided that screening and monitoring of participants 
is strengthened and measures are implemented to ensure the safe 
management of any participants who develop this extraordinarily 
rare complication of vaccination.
To this end, the South African Society of Thrombosis and Haemo-
stasis has developed recommendations for the diagnosis and manage-
ment of vaccine-induced immune thrombotic thrombocytopenia 
(VITT), which are based on the recommendations for the manage-
ment of an equally rare disorder, heparin-induced thrombocyto-
penia with thrombosis (HITT). These will be updated as new 
evidence becomes available.[3] 
At the time of writing, SAHPRA are still deliberating on exactly 
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